Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Thursday.
Other equities research analysts have also issued reports about the stock. Credit Suisse Group set a $420.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, April 27th. Leerink Swann set a $435.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 4th. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $400.00 to $370.00 and set an “equal weight” rating on the stock in a research note on Friday, May 4th. Cowen reissued a “hold” rating and set a $400.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, April 27th. Finally, Canaccord Genuity lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the stock from $522.00 to $356.00 in a research note on Wednesday, February 21st. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have given a buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average target price of $426.88.
REGN stock opened at $331.97 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.94 and a current ratio of 3.59. Regeneron Pharmaceuticals has a 52-week low of $281.89 and a 52-week high of $529.99. The stock has a market cap of $35.44 billion, a PE ratio of 24.76, a PEG ratio of 1.18 and a beta of 1.40.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 3rd. The biopharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.08 by ($0.41). Regeneron Pharmaceuticals had a return on equity of 29.92% and a net margin of 23.54%. The firm had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the previous year, the company earned $2.92 earnings per share. The company’s revenue was up 14.6% compared to the same quarter last year. sell-side analysts forecast that Regeneron Pharmaceuticals will post 17.2 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 74,710 shares of the stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $327.87, for a total value of $24,495,167.70. Following the completion of the sale, the chairman now owns 553,121 shares in the company, valued at approximately $181,351,782.27. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Sanofi sold 121,601 shares of the stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $309.31, for a total transaction of $37,612,405.31. The disclosure for this sale can be found here. In the last quarter, insiders sold 214,718 shares of company stock valued at $67,470,695. 12.42% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the business. Yong Rong HK Asset Management Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $2,583,000. Suntrust Banks Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 17.6% during the 1st quarter. Suntrust Banks Inc. now owns 2,665 shares of the biopharmaceutical company’s stock worth $917,000 after buying an additional 398 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Regeneron Pharmaceuticals by 10.9% during the 1st quarter. Amalgamated Bank now owns 11,569 shares of the biopharmaceutical company’s stock worth $3,984,000 after buying an additional 1,138 shares during the last quarter. Summit Trail Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 22,971.8% during the 1st quarter. Summit Trail Advisors LLC now owns 166,348 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 165,627 shares during the last quarter. Finally, CIBC World Markets Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 30.4% during the 1st quarter. CIBC World Markets Inc. now owns 2,081 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 485 shares during the last quarter. Institutional investors own 66.22% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.